Pluristem Therapeutics to Present at theSecond Annual Life Science Conference of The Society of Investment Professionals in Germany

NEW YORK--(Business Wire)--
Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics
company dedicated to the commercialization of unrelated donor-patient
(allogeneic) cell therapy products for a variety of disorders, announced today
that Mr. Thomas Klein, Pluristem`s EU representative, will present at the
conference of the Society of Investment Professionals in Germany, the DVFA, on
"The Placenta, from the Miracle of Birth to Therapeutics to All". This is the
second annual Life Science Conference for the DVFA and Pluristem will present on
Tuesday, June 16, 2009 at the DVFA Center, Frankfurt, Germany.

"The German investment community has expressed a great interest in Pluristem
over the last several months, which goes hand in hand with the scientific and
clinical collaborations that Pluristem has in Germany," stated Zami Aberman,
Chairman, President and CEO of Pluristem. "We look forward to treating our first
patient in a Phase-I trial utilizing PLX-PAD, our placental-derived cellular
product for the treatment of Peripheral Artery Disease in Germany."

About Pluristem

Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the
commercialization of unrelated donor-patient (allogeneic) cell therapy products
for the treatment of several severe degenerative, ischemic and autoimmune
disorders. The Company is developing a pipeline of products derived from the
human placenta, a non-controversial, non-embryonic, adult stem cell source. The
PLacental eXpanded cell products (PLX) are stored off-the-shelf, ready-to-use,
and require no matching.

These placental adherent stromal cells (ASCs) are expanded in the Company's
proprietary PluriXTM 3D bioreactor system, which provides a 3D microenvironment
that enables large-scale growth of these cells without the need for supplemental
growth factors or other exogenous materials. PLX cells are immune privileged,
possess immunomodulatory properties, and are expanded in vitro without showing
signs of phenotypic or karyotypic changes. Pluristem believes that the PLX
cells` mechanism of action may be related to the secretion of cytokines and/or
other potent immune modulators.

Pluristem's first product, PLX-PAD (for the treatment of Peripheral Artery
Disease), received FDA clearance to begin a "First-In-Human" placental-derived
mesenchymal-like stromal cell clinical trial.

The Company's additional product candidates include PLX-IBD, targeting
Inflammatory Bowel Disease (IBD), which includes Crohn`s disease and Ulcerative
Colitis; PLX-MS, targeting Multiple Sclerosis; PLX-BMT, targeting the global
shortfall of matched tissue for bone marrow transplantation (BMT) by improving
the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord
blood; and PLX-STROKE, targeting ischemic stroke.

Pluristem has offices in the USA with research and manufacturing facilities in
Israel.

See our product animation on YouTube: Animation, the content of which is not
part of this press release.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act of 1995
and federal securities laws. For example, when we say that we look forward to
treating our first patient in a Phase-I trial utilizing PLX-PAD, our
placental-derived cellular product for the treatment of Peripheral Artery
Disease in Germany, we are using forward-looking statements. These
forward-looking statements are based on the current expectations of the
management of Pluristem only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. The following factors, among
others, could cause actual results to differ materially from those described in
the forward-looking statements: changes in technology and market requirements;
our technology may not be validated as we progress further and our methods may
not be accepted by the scientific community; we may be unable to retain or
attract key employees whose knowledge is essential to the development of our
products; unforeseen scientific difficulties may develop with our process;
results in the laboratory may not translate to equally good results in real
surgical settings; our patents may not be sufficient; our products may harm
recipients; changes in legislation; inability to timely develop and introduce
new technologies, products and applications; loss of market share and pressure
on pricing resulting from competition, which could cause the actual results or
performance of Pluristem to differ materially from those contemplated in such
forward-looking statements. Except as otherwise required by law, Pluristem
undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. For a more detailed
description of the risk and uncertainties affecting Pluristem, reference is made
to Pluristem's reports filed from time to time with the Securities and Exchange
Commission.

For more information visit our website at www.pluristem.com, the content of
which is not part of this press release.

Pluristem Therapeutics Inc.
William Prather RPh, MD, +1-303-883-4954
Sr. VP Corporate Development
William.PratherMD@pluristem.com

Copyright Business Wire 2009